Asterias Biotherapeutics Inceries A (NYSEAMERICAN:AST) had a decrease of its shares shorted by 4.81%. FINRA announced in March AST’s total 409,700 shares shorted. That’s 4.81% down from 430,400 shares. 5 days will cost AST with 77,200 average volume to restore its previous position. Asterias Biotherapeutics Inceries A’s shares shorted float is 1.47%.

The stock decreased 2.25% or $0.02 during the last trading session, reaching $0.87.Asterias Biotherapeutics, Inc. has volume of 30,777 shares. Since March 6, 2018 AST has declined 57.56% and is downtrending. The stock underperformed the S&P 500 by 61.93%.

Asterias Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing novel therapies in the fields of cell therapy and regenerative medicine.The company has $48.42 million market cap. The firm develops therapeutic products in the areas of neurology and oncology.Currently it has negative earnings. The Company’s clinical stage programs include AST-OPC1, a therapy derived from pluripotent stem cells that has completed a Phase I clinical trial for the treatment of thoracic spinal cord injuries; and that is in Phase I/IIa clinical trial for treating cervical spinal cord injuries, as well as for the treatment of multiple sclerosis and white matter stroke.